ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Hisamitsu Pharmaceutical Co., Inc.

Business Summary

Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat brands. It also provides ethical pharmaceuticals, over- the-counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.

Financial Highlights

Feb 2022 JPYUSD
Revenue120,193M1,077.96M
Gross Profit70,067M628.40M
Operating income9,337M83.74M
Income before tax12,956M116.19M
Net income9,658M86.61M
EBITDA13,658M122.49M
Diluted EPS118.831.06
Dividends Per Share840.75
Total Assets302,858M2,629.54M
Total liabilities47,969M416.48M
Total equity253,168M2,198.11M
Operating cash flow19,199M172.18M
Currency in JPYCurrency in USD

Historical Data

 Feb 2018Feb 2019Feb 2020Feb 2021Feb 2022
Revenue 147,870M 143,408M 140,992M 114,510M 120,193M
Gross Profit 92,182M 88,681M 87,604M 69,173M 70,067M
Operating income 26,346M 22,280M 22,729M 10,672M 9,337M
Income before tax 27,694M 25,673M 26,155M 12,197M 12,956M
Net income 19,120M 19,204M 18,694M 9,251M 9,658M
EBITDA 32,351M 28,022M 26,980M 14,751M 13,658M
Diluted EPS 228.34 229.85 227.29 113.10 118.83
Dividends Per Share 82 82.50 83 83.50 84
Total Assets 299,913M 295,786M 307,401M 299,861M 302,858M
Total liabilities 54,681M 47,154M 56,652M 46,048M 47,969M
Total equity 244,000M 247,334M 249,276M 252,299M 253,168M
Operating cash flow 30,453M 15,772M 27,395M 5,289M 19,199M
 Feb 2018Feb 2019Feb 2020Feb 2021Feb 2022
Revenue 1,327.30M 1,298.05M 1,293.38M 1,080.68M 1,077.96M
Gross Profit 827.44M 802.69M 803.63M 652.81M 628.40M
Operating income 236.48M 201.66M 208.50M 100.71M 83.74M
Income before tax 248.58M 232.37M 239.93M 115.10M 116.19M
Net income 171.62M 173.82M 171.48M 87.30M 86.61M
EBITDA 290.38M 253.63M 247.50M 139.21M 122.49M
Diluted EPS 2.04 2.08 2.08 1.06 1.06
Dividends Per Share 0.73 0.74 0.76 0.78 0.75
Total Assets 2,810.67M 2,657.07M 2,849.86M 2,814.53M 2,629.54M
Total liabilities 512.45M 423.58M 525.21M 432.21M 416.48M
Total equity 2,286.67M 2,221.82M 2,310.99M 2,368.11M 2,198.11M
Operating cash flow 273.35M 142.75M 251.30M 49.91M 172.18M

Valuation Measures

Feb 2022
PER30.77
ROA3.20%
ROE3.82%
Operating margin7.76%
Profit margin8.03%

Key executives

  • President & Representative Director: Kazuhide Nakatomi
  • Director, Executive Officer, Manager-Finance & IR: Shinichiro Takao
  • Senior Executive Officer, GM-R&D: Takaaki Terahara
  • Director, Manager-Legal Affairs & Head-Compliance: Nobuo Tsutsumi
  • MD, Executive Officer & Head-Operations: Tetsuo Akiyama

Shareholders

  • Hisamitsu Pharmaceutical Co., Inc. (7.4%)
  • Nishi Nippon City Bank Pension Fund (5.1%)
  • MUFG Bank Pension Fund (5.0%)
  • Nippon Life Insurance Co. (4.5%)
  • Government of Japan (4.0%)
  • Fukuoka Financial Group, Inc. (3.9%)
  • Hisamitsu Pharmaceutical Business Association (2.8%)
  • The Bank of Saga Ltd. (2.7%)
  • Sumitomo Mitsui Banking Pension Fund (2.4%)
  • Mitsubishi UFJ Financial Group, Inc. (2.1%)

Contact Details

Related Companies

  • Hisamitsu Italia Srl
  • Hisamitsu Agency Co., Ltd
  • Hisamitsu Pharmaceutical (Hong Kong) Co., Ltd.
  • Hisamitsu Pharmaceutical (China) Co., Ltd.
  • Nakatomi Memorial Foundation
  • Hisamitsu Pharmaceutical Co., Ltd
  • Hisamitsu Farmaceutica do Brasil Ltda.
  • Hisamitsu Vietnam Pharmaceutical Co., Ltd.
  • PT Hisamitsu Pharma Indonesia
  • Hisamitsu UK Ltd.
  • Hisamitsu Pharmaceutical Business Association
  • Hisamitsu Pharmaceutical Tech Consulting (Beijing) Co., Ltd.
  • CRCC Media Co., Ltd.
  • Hisamitsu America, Inc.
  • Saga City-Vision Co., Ltd.
  • Hisamitsu U.S., Inc.
  • SSP Co. Ltd. /Ethical Medicine Division/
  • Taiyo Co., Ltd
  • Noven Pharmaceuticals, Inc.

Competitors

  • KemPharm, Inc.
  • Icure Pharmaceutical Incorporation
Last Updated on 27 Jan, 2023

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more